Innovation in

PharmCode is a platform technology to select and apply Intrabodies to validating intracellular drug targets. Intrabodies can target protein-protein, phosphorylation and events cytoplasmic signaling pathways using dose and affinity to demonstrate pharmacologically relevant events. Intrabodies can validate drug targets and function as drugs to treat a wide range of diseases such as cancer, chronic and acute inflammatory disease, infectious disease and autoimmune disease.


September 3, 2013
Vybionís Huntington Drug Neutralizes Critical Disease Driver More»

March 28, 2012
Vybion announces the availability of PharmCode for partnering. More»

September 28, 2011
Vybion has been notified by the US Patent office of the issue of Patent No. 8,029,985 on October 4, 2011 entitled "Amplified Bioassay". More»

Huntingtonís Disease

The first therapeutic to emerge from PharmCode is INT41, an intrabody delivered with AAV6 for the treatment of Huntingtonís disease. INT41 is a disease modifying drug that blocks gene dysregulation and the action of toxic Huntingtin mutant protein fragments in the nucleus.